A- A A+

Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis. 

Artenie A, Stone J, Facente SN, Fraser H, Hecht J, Rhodes P, McFarland W, Wilson E, Hickman M, Vickerman P, Morris MD. 

J Infect Dis. 2023 Sep 15;228(6):662-673. doi: 10.1093/infdis/jiad169. PMID: 37486337; PMCID: PMC10503949.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503949/

Reinfection incidence and risk among people treated for recent hepatitis C virus infection: the react study. 

Martinello, Marianne; Carson, Joanne M.; Van Der Valk, Marc; Rockstroh, Jürgen K.; Ingiliz, Patrick; Hellard, Margaret; Nelson, Mark; Lutz, Thomas; Bhagani, Sanjay; Kim, Arthur Y.; Hull, Mark; Cordes, Christiane; Moon, Juhi; Feld, Jordan J.; Gane, Ed; Rauch, Andri; Bruneau, Julie; Tu, Elise; Applegate, Tanya; Grebely, Jason; Dore, Gregory J.; Matthews, Gail V.. 

AIDS ():10.1097/QAD.0000000000003651, July 18, 2023. | DOI: 10.1097/QAD.0000000000003651 

Abstract

https://journals.lww.com/aidsonline/abstract/9900/reinfection_incidence_and_risk_among_people.308.aspx

Global burden of liver disease: 2023 update

Devarbhavi, Harshad et al.

Journal of Hepatology, Volume 79, Issue 2, 516 - 537 

https://www.journal-of-hepatology.eu/article/S0168-8278(23)00194-0/fulltext

Cost-effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO-HCV trial. 

Lim, AG, Aas, CF, Çağlar, ES, Vold, JH, Fadnes, LT, Vickerman, P, et al. Addiction. 2023. doi.org/10.1111/add.16305

https://onlinelibrary.wiley.com/doi/full/10.1111/add.16305

Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study. 

Ilhame A, Cécile D, Camelia P, David M, Joris H, Adélaïde P, Danièle B, Patrizia C, Perrine R. 

Harm Reduct J. 2023 Jul 29;20(1):98. doi: 10.1186/s12954-023-00841-7. PMID: 37516889; PMCID: PMC10387207.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387207/

"Treated like a Human Being": perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City. 

Kapadia SN, Aponte-Melendez Y, Rodriguez A, Pai M, Eckhardt BJ, Marks KM, Fong C, Mateu-Gelabert P. 

Harm Reduct J. 2023 Jul 27;20(1):95. doi: 10.1186/s12954-023-00831-9. PMID: 37501180; PMCID: PMC10375754.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375754/

Providing Hepatitis C Treatment Locally for Substance-Using Patients. 

Clapp SB, Johnson CB. 

J Prim Care Community Health. 2023 Jan-Dec;14:21501319231186355. doi: 10.1177/21501319231186355. PMID: 37424381; PMCID: PMC10336754.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336754/

Hepatitis C antibody test frequencies and positive rates in Switzerland from 2007 to 2017: a retrospective longitudinal study. 

Agosti-Gonzalez R, Falcato L, Grischott T, Senn O, Bruggmann P. 

Swiss Med Wkly. 2023 Jun 5;153:40085. doi: 10.57187/smw.2023.40085. PMID: 37410941.

https://smw.ch/index.php/smw/article/view/3345

The eliminate hepatitis C (EC) experience study: baseline characteristics of a cohort of people who inject drugs in Melbourne, Australia. 

Gunn J, O'Keefe D, Draper BL, Djordjevic F, Ryan K, Kerr P, Elsum I, Gold J, Layton C, Chan K, Dietze P, Higgs P, Doyle J, Stoové MA, Hellard M, Pedrana A. 

BMJ Open. 2023 Jul 3;13(7):e071665. doi: 10.1136/bmjopen-2023-071665. PMID: 37400235; PMCID: PMC10335404.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335404/

Hepatitis C: Auch nach der Ausheilung bleibt das Sterberisiko deutlich erhöht

Glasgow – Mit den neuen direkten antiviralen Medikamenten (DAA) kann eine Hepatitis C fast immer geheilt werden. Dies bedeutet allerdings nicht, dass das Sterberisiko der Patienten normalisiert wird, wie die Erfah­rungen aus drei Kohortenstudien im Britischen Ärzteblatt (BMJ 2023; DOI: 10.1136/bmj-2022074001) zeigen. (aerzteblatt.de, 04.08.2023)

https://www.aerzteblatt.de/nachrichten/145053/Hepatitis-C-Auch-nach-der-Ausheilung-bleibt-das-Sterberisiko-deutlich-erhoeht

Deutlicher Anstieg von Hepatitis B und Hepatitis C

Berlin – Im Jahr 2022 sind dem Robert-Koch-Institut 16.144 HBV- und 7.919 HCV-Fälle gemeldet worden. Dies ist ein deutlicher Anstieg gegenüber den Jahren 2019 bis 2021, in denen im Mittel pro Jahr 8.240 Hepatitis-B- und 5.097 Hepatitis-C-Fälle übermittelt wurden.

Neben dem neuen Screening für Kassenpatienten ab 35 Jahren und der Einführung der elektronischen Labor­meldungen dürfte nach einem Beitrag im Epidemiologischen Bulletin 31/2023 vor allem die Fluchtmigration aus der Ukraine eine Rolle spielen. (aerzteblatt.de, 08.08.2023)

https://www.aerzteblatt.de/nachrichten/145071/Deutlicher-Anstieg-von-Hepatitis-B-und-Hepatitis-C

Hepatitis B and C in Europe: an update from the Global Burden of Disease Study 2019

Cortesi, Paolo Angelo et al.

The Lancet Public Health, Volume 8, Issue 9, e701 - e716 

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(23)00149-4/fulltext

A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study

Sheehan, Yumi et al.

Journal of Hepatology, Volume 79, Issue 3, 635 - 644 

https://www.journal-of-hepatology.eu/article/S0168-8278(23)00242-8/fulltext

RKI. Epidemiologisches Bulletin: Welt-Hepatitis-Tag: Hepatitis B und Hepatitis C in Deutschland 2022 - Anstieg der übermittelten Hepatitis-B- und Hepatitis-C-Fälle in Deutschland im Jahr 2022.

Im Jahr 2022 konnte für Deutschland ein stetiger bundesweiter Anstieg der übermittelten Infektionen mit dem Hepatitis-B-Virus (HBV) und dem Hepatitis-C-Virus (HCV) beobachtet werden. Mehrere Ereignisse in den Jahren 2021/2022 haben diesen Anstieg möglicherweise beeinflusst: Das im Oktober 2021 eingeführte HBV- und HCV-Screening für alle Personen ab 35 Jahre im Rahmen der Gesundheitsuntersuchung für gesetzlich Versicherte, die Einführung der elektronischen Labormeldungen über das Deutsche Elektronische Melde- und Informationssystem für den Infektionsschutz (DEMIS) und die Fluchtmigration aus der Ukraine, wo die Prävalenz von HBV- und HCV-Infektionen höher ist als in Deutschland. Anlässlich des diesjährigen Welt-Hepatitis-Tages werden die Auswirkungen dieser Ereignisse auf den beobachteten Anstieg untersucht und die hierzu verwendeten Methoden sowie die Ergebnisse detailliert dargestellt. (RKI, Epidemiologsches Bulletin, 41/2023, 31.08.2023)

https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2023/Ausgaben/31_23.pdf

Risk of Hepatocellular Carcinoma After Spontaneous Clearance of Hepatitis C Virus and in Noncirrhosis Chronic Hepatitis C Patients With Sustained Virological Response: A Systematic Review. 

Hsu CC, Gopalakrishna H, Mironova M, Lee MH, Chen CJ, Yang HI, Wiese M, Chang KM, Wright EC, Abijo T, Feld JJ, Kaplan DE. 

Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S245-S256. doi: 10.1093/cid/ciad380. PMID: 37579210; PMCID: PMC10425144.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425144/

Analysis of Patients' Characteristics and Treatment Profile of People Who Use Drugs (PWUDs) with and without a Co-Diagnosis of Viral Hepatitis C: A Real-World Retrospective Italian Analysis. 

Nava FA, Mangia A, Riglietta M, Somaini L, Foschi FG, Claar E, Maida I, Ucciferri C, Frigerio F, Hernandez C, Dovizio M, Perrone V, Degli Esposti L, Puoti M. 

Ther Clin Risk Manag. 2023 Aug 4;19:645-656. doi: 10.2147/TCRM.S409134. PMID: 37560130; PMCID: PMC10408688.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408688/

Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment. 

Talal AH, George SJ, Talal LA, Dharia A, Ventuneac A, Baciewicz G, Perumalswami PV, Dickerson SS. 

Res Involv Engagem. 2023 Aug 2;9(1):63. doi: 10.1186/s40900-023-00474-x. PMID: 37533127; PMCID: PMC10399008.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399008/

Training the healthcare workforce: the global experience with telementorship for hepatitis B and hepatitis C. 

Corcorran MA, Thornton K, Struminger B, Easterbrook P, Scott JD. 

BMC Health Serv Res. 2023 Aug 2;23(1):824. doi: 10.1186/s12913-023-09849-y. PMID: 37533025; PMCID: PMC10394928.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394928/

Mortality rates among patients successfully treated for hepatitis C in the era of interferon-free antivirals: population based cohort study. 

Hamill V, Wong S, Benselin J, Krajden M, Hayes PC, Mutimer D, Yu A, Dillon JF, Gelson W, Velásquez García HA, Yeung A, Johnson P, Barclay ST, Alvarez M, Toyoda H, Agarwal K, Fraser A, Bartlett S, Aldersley M, Bathgate A, Binka M, Richardson P, Morling JR, Ryder SD, MacDonald D, Hutchinson S, Barnes E, Guha IN, Irving WL, Janjua NZ, Innes H. 

BMJ. 2023 Aug 2;382:e074001. doi: 10.1136/bmj-2022-074001. PMID: 37532284; PMCID: PMC10394680.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394680/

The eliminate hepatitis C (EC) experience study: baseline characteristics of a cohort of people who inject drugs in Melbourne, Australia. 

Gunn J, O'Keefe D, Draper BL, Djordjevic F, Ryan K, Kerr P, Elsum I, Gold J, Layton C, Chan K, Dietze P, Higgs P, Doyle J, Stoové MA, Hellard M, Pedrana A. 

BMJ Open. 2023 Jul 3;13(7):e071665. doi: 10.1136/bmjopen-2023-071665. PMID: 37400235; PMCID: PMC10335404.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335404/

Improving HIV and HCV Testing in Substance Use Disorder Programs (SUDs) That Provide Medications for Opiate Use Disorder (MOUD): Role of Addressing Barriers and Implementing Universal and Site-Specific Approaches. 

Brooks R, Wegener M, Freeman B, et al. 

Health Promotion Practice. 2023;0(0). doi:10.1177/15248399231169791

https://journals.sagepub.com/doi/10.1177/15248399231169791

Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis

Aghaei, Ardavan Mohammad et al.

The Lancet Global Health, Volume 11, Issue 8, e1225 - e1237 

https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00267-X/fulltext

Additional challenges in reaching hepatitis C elimination goals in Germany due to the COVID-19 pandemic - descriptive analysis of drug prescription data from January 2018 to June 2021. 

Meyer ED, Dudareva S, Kollan C, Mauss S, Wedemeyer H, Schmidt D, Zimmermann R. 

Front Public Health. 2023 May 30;11:1149694. doi: 10.3389/fpubh.2023.1149694. PMID: 37325322; PMCID: PMC10267983.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267983/

HCV prevalence and treatment outcomes among drug users in an outpatient center for drug addiction in Northern Italy. 

Lanza A, Olivola M, Peschi G, Brondino N, Politi P. 

Ann Ist Super Sanita. 2023 Apr-Jun;59(2):108-113. doi: 10.4415/ANN_23_02_03. PMID: 37337985.

https://www.iss.it/documents/20126/0/ANN_23_02_03.pdf

A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences. 

Karasz A, Merchant K, Arnsten J, Feinberg J, Kim AY, Lum PJ, McKee MD, Mehta SH, Meissner P, Norton BL, Page K, Pericot-Valverde I, Singh R, Stein E, Taylor LE, Tsui JI, Wagner K, Litwin A. 

J Med Internet Res. 2023 Jun 2;25:e38176. doi: 10.2196/38176. PMID: 37266986; PMCID: PMC10276322.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276322/

HIV and Hepatitis C Risk among Tajik Migrant Workers Who Inject Drugs in Moscow. 

Mackesy-Amiti ME, Levy JA, Bahromov M, Jonbekov J, Luc CM. 

Int J Environ Res Public Health. 2023 May 24;20(11):5937. doi: 10.3390/ijerph20115937. PMID: 37297541; PMCID: PMC10252367.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252367/

Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden. 

Lindqvist K, Thorin Z, Kåberg M. 

Harm Reduct J. 2023 Jun 12;20(1):72. doi: 10.1186/s12954-023-00801-1. PMID: 37308951; PMCID: PMC10258779.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258779/

Hepatitis C virus seroprevalence among patients enrolled at the opioid substitution therapy center in Bihar: A cross-sectional study. 

Kumar A, Mahajan H, Chaturvedi S, Kumar A, Kumar S, Sahoo GC, et al. (2023) 

PLoS ONE 18(6): e0287333. doi.org/10.1371/journal.pone.0287333

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0287333

Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden. 

Kågström E, Lannergård A, El Khosht J, Lörelius P, Månflod J, Strömdahl S. 

Harm Reduct J. 2023 Jun 16;20(1):77. doi: 10.1186/s12954-023-00806-w. PMID: 37328868; PMCID: PMC10273738.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273738/

Injection partnership characteristics and HCV status associations with syringe and equipment sharing among people who inject drugs. 

Mackesy-Amiti ME, Boodram B, Page K, Latkin C. 

BMC Public Health. 2023 Jun 20;23(1):1191. doi: 10.1186/s12889-023-16133-5. PMID: 37340398; PMCID: PMC10283252.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10283252/

  1. Rapid hepatitis C virus point-of-care RNA testing and treatment at an integrated supervised consumption service in Toronto, Canada: a prospective, observational cohort study. 
  2. Hepatitis C Infection and Treatment among Injecting Drug Users Attending General Practice: A Systematic Review and Meta-Analysis. 
  3. Time-to-hepatitis C treatment initiation among people who inject drugs in Melbourne, Australia. 
  4. Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs - a scoping review of the qualitative evidence. 
  5. Hepatitis C treatment uptake among people who inject drugs in Oslo, Norway: A registry-based study.